Monica Stonehill

There are approximately 100,000 alcohol-related cancer cases annually in the U.S. and 20,000 deaths due to alcohol-related cancer, according to an HHS press release.This is one of the many tipping points that sparked U.S. Surgeon General Vivek Murthy, MD, MBA, to issue an advisory designed to raise awareness about alcohol consumption and reduce the incidence of alcohol-related cancers and deaths.

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.In July, the FDA approved Guardant Health’s Shield, the first blood test approved as a primary CRC screening option. It joins the pipeline of noninvasive screening

Glucagon-like peptide-1 receptor agonist use for obesity management continues to rise, but not without concerns for use during elective surgery – uncertainty remains over whether halting them beforehand is the safest option for patients.In June 2023, the American Society of Anesthesiologists recommended holding GLP-1s at least 1 week prior to any elective surgery that required sedation due

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the mounting threat of cyberattacks on health care organizations and how employees are often “the weakest link” in their defense. In this month’s Healio Exclusive, Healio reported on the aftermath of the Feb. 21st ransomware attack on Change Healthcare that required it to pay $22 million in ransom to regain control

Black and Native Hawaiian or other Pacific Islander patients with early-onset colorectal cancer had higher risk for mortality compared with white patients, with data supporting the role of social determinants of health in those differences. “Although published data has pointed to the rise in incidence of early-onset CRC among several racial and ethnic groups, our results indicate that there

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting. “GLP-1RAs are quickly becoming the cornerstone of diabetes and weight loss management,” Mohammad S. Siddiqui, MD, from the Virginia

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data. “Metabolic dysfunction-associated steatohepatitis represents a significant unmet medical need, as it is one of the leading causes of liver transplantation in the

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease. “Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are primarily used for glycemic control in patients with diabetes and have recently been approved for weight

SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data. “MASLD is the commonest liver disease in the world and the fastest rising cause of liver cancer,” Binu John, MD, MPH, chief of

PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter. “Our goal was to provide clinicians with clearer guidance on which medication might offer better outcomes in terms of efficacy and safety in AIH